Literature DB >> 20410162

Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis.

Johanna Sandgren1, Teresita Diaz de Ståhl, Robin Andersson, Uwe Menzel, Arkadiusz Piotrowski, Helena Nord, Martin Bäckdahl, Nimrod B Kiss, Michael Brauckhoff, Jan Komorowski, Henning Dralle, Ola Hessman, Catharina Larsson, Göran Akerström, Carl Bruder, Jan P Dumanski, Gunnar Westin.   

Abstract

Pheochromocytomas and abdominal paragangliomas are adrenal and extra-adrenal catecholamine-producing tumours. They arise due to heritable cancer syndromes, or more frequently occur sporadically due to an unknown genetic cause. The majority of cases are benign, but malignant tumours are observed. Previous comparative genomic hybridization (CGH) and loss of heterozygosity studies have shown frequent deletions of chromosome arms 1p, 3q and 22q in pheochromocytomas. We applied high-resolution whole-genome array CGH on 53 benign and malignant pheochromocytomas and paragangliomas to narrow down candidate regions as well as to identify chromosomal alterations more specific to malignant tumours. Minimal overlapping regions (MORs) were identified on 16 chromosomes, with the most frequent MORs of deletion (> or = 32%) occurring on chromosome arms 1p, 3q, 11p/q, 17p and 22q, while the chromosome arms 1q, 7p, 12q and 19p harboured the most common MORs of gain (> or = 14%). The most frequent MORs (61-75%) in the pheochromocytomas were identified at 1p, and the four regions of common losses encompassed 1p36, 1p32-31, 1p22-21 and 1p13. Tumours that did not show 1p loss generally demonstrated aberrations on chromosome 11. Gain of chromosomal material was significantly more frequent among the malignant cases. Moreover, gain at 19q, trisomy 12 and loss at 11q were positively associated with malignant pheochromocytomas, while 1q gain was commonly observed in the malignant paragangliomas. Our study revealed novel and narrow recurrent chromosomal regions of loss and gain at several autosomes, a prerequisite for identifying candidate tumour suppressor genes and oncogenes involved in the development of adrenal and extra-adrenal catecholamine-producing tumours.

Entities:  

Mesh:

Year:  2010        PMID: 20410162     DOI: 10.1677/ERC-09-0310

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  16 in total

1.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

2.  Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling.

Authors:  Alessandro Cama; Fabio Verginelli; Lavinia Vittoria Lotti; Francesco Napolitano; Annalisa Morgano; Andria D'Orazio; Michele Vacca; Silvia Perconti; Felice Pepe; Federico Romani; Francesca Vitullo; Filippo di Lella; Rosa Visone; Massimo Mannelli; Hartmut P H Neumann; Giancarlo Raiconi; Carlo Paties; Antonio Moschetta; Roberto Tagliaferri; Angelo Veronese; Mario Sanna; Renato Mariani-Costantini
Journal:  Acta Neuropathol       Date:  2013-08-18       Impact factor: 17.088

Review 3.  Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.

Authors:  Ales Vicha; David Taieb; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2014-05-08       Impact factor: 5.678

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

5.  Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Authors:  Nadia Passon; Elisa Bregant; Marialuisa Sponziello; Maria Dima; Francesca Rosignolo; Cosimo Durante; Marilena Celano; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

Review 6.  Rethinking pheochromocytomas and paragangliomas from a genomic perspective.

Authors:  L J Castro-Vega; C Lepoutre-Lussey; A-P Gimenez-Roqueplo; J Favier
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

Review 7.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

Review 8.  Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?

Authors:  Esther Korpershoek; Karel Pacak; Lucia Martiniova
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

9.  Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.

Authors:  Luis Jaime Castro-Vega; Eric Letouzé; Nelly Burnichon; Alexandre Buffet; Pierre-Hélie Disderot; Emmanuel Khalifa; Céline Loriot; Nabila Elarouci; Aurélie Morin; Mélanie Menara; Charlotte Lepoutre-Lussey; Cécile Badoual; Mathilde Sibony; Bertrand Dousset; Rossella Libé; Franck Zinzindohoue; Pierre François Plouin; Jérôme Bertherat; Laurence Amar; Aurélien de Reyniès; Judith Favier; Anne-Paule Gimenez-Roqueplo
Journal:  Nat Commun       Date:  2015-01-27       Impact factor: 17.694

10.  Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.

Authors:  Nimrod B Kiss; Andreas Muth; Adam Andreasson; C Christofer Juhlin; Janos Geli; Martin Bäckdahl; Anders Höög; Bo Wängberg; Ola Nilsson; Håkan Ahlman; Catharina Larsson
Journal:  Endocr Relat Cancer       Date:  2013-02-18       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.